Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15086448 | 0.85 | KDM4E (0.52) | NAMPTKDM4EMAPTTHRBPDE4B | |
| SCHEMBL14635623 | 0.81 | NAMPT (0.58) | NAMPTKDM4EMAPTTHRBPDE4B | |
| SCHEMBL17404613 | 0.80 | GPR119 (0.54) | NAMPTKDM4EMAPTTHRBPDE4B | |
| SCHEMBL16150994 | 0.80 | NAMPT (0.52) | NAMPTKDM4EMAPTTHRBPDE4B | |
| SCHEMBL15066063 | 0.79 | KDM4E (0.47) | NAMPTKDM4EMAPTTHRBPDE4B | |
| SCHEMBL23411376 | 0.78 | GPR119 (0.48) | NAMPTKDM4EMAPTTHRBPDE4B | |
| SCHEMBL23442866 | 0.77 | GPR119 (0.48) | NAMPTKDM4EMAPTTHRBPDE4B | |
| SCHEMBL24309415 | 0.77 | NAMPT (0.52) | NAMPTKDM4EMAPTTHRBPDE4B | |
| SCHEMBL29567337 | 0.77 | NAMPT (0.52) | NAMPTKDM4EMAPTTHRBPDE4B | |
| SCHEMBL31728977 | 0.77 | NAMPT (0.49) | NAMPTKDM4EMAPTTHRBPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083583-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF | SAGIMET BIOSCIENCES INC (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3083583-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF | SAGIMET BIOSCIENCES INC (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-2870150-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3 V BIOSCIENCES INC (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-2870150-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3 V BIOSCIENCES INC (US) | 2019-06-19 | — | — | EP | disclosed |
| US-10226449-B2 | Heterocyclic modulators of lipid synthesis and combinations thereof | 3-V BIOSCIENCES, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10226449-B2 | Heterocyclic modulators of lipid synthesis and combinations thereof | 3-V BIOSCIENCES, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10118913-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| US-10053450-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180222892-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180222892-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| EP-3083583-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF | 3-V Biosciences, Inc. (US) | 2016-10-26 | — | — | EP | disclosed |
| US-9428502-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428502-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428502-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150210688-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150210688-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150210688-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2015095767-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF | 3-V BIOSCIENCES, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095767-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF | 3-V BIOSCIENCES, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2014008197-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10118913-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, FADS2 | FASN 1/4885NAMPT 235/4885KDM4E 2502/4885 |
| US-10053450-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, FADS2 | FASN 1/4885NAMPT 235/4885KDM4E 2502/4885 |
| US-20180222892-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | FASN 1/4885NAMPT 235/4885KDM4E 2502/4885 |
| US-10226449-B2 | Heterocyclic modulators of lipid synthesis and combinations thereof | FASN, FADS1, COASY | FASN 1/4885NAMPT 239/4885KDM4E 2053/4885 |
| US-20150210688-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | FASN 1/4885NAMPT 235/4885KDM4E 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.